Combination antitumor therapy
US9198893B2 · kind B2 · utility
4Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2009 |
| Grant date | Dec 1, 2015 |
| Priority date | — |
| Expiry date | Jun 20, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.